 |
Generex Announces Patent Award for its Core Vaccine Technologies in Japan
Feb 1, 2012
|
11.9 KB |
| |
WORCESTER, Mass. and TORONTO, Feb. 1, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded a Japanese Patent centering on its Ii-Key technology for the development of immunotherapeutic vaccines. A number of products developed with this tech...
|
|
Generex Announces $2.00 Million Capital Investment
Jan 31, 2012
|
12.7 KB |
| |
WORCESTER, Mass. and TORONTO, Jan. 31, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (the "Company" or "Generex") (www.generex.com) (OTCBB: GNBT) today announced that it entered into a securities purchase agreement with certain institutional investors on January 31, 2012. The investors have agreed to purchase an aggregate of 2,000 shares ...
|
|
Generex Secures Commitments for $3.6M Capital Raise
Jan 25, 2012
|
9.6 KB |
| |
WORCESTER, Mass. and TORONTO, Jan. 25, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that it has secured two commitments for an aggregate capital raise of CA$3,600,000. This funding is structured as term loans of one year from private lenders secured by the Company's real estate. Interest on the loans is pay...
|
|
Generex Subsidiary Antigen Express Featured on SNN Stock News Now; Highlights Advantages of Ii-Key Platform Technology for Cancer Immunotherapy
Jan 17, 2012
|
13.9 KB |
| |
WORCESTER, Mass. and TORONTO, Jan. 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that a detailed interview conducted at the BioTech Showcase 2012 during last week's JPMorgan Healthcare Conference in San Francisco with Dr. Eric von Hofe, Ph.D., President of Generex subsidiary Antigen Express, Inc., regar...
|
|
Generex Subsidiary Antigen Express Available for Partnering & Collaboration Meetings at the 2012 JPMorgan Healthcare Conference
Jan 5, 2012
|
13.0 KB |
| |
WORCESTER, Mass. and TORONTO, Jan. 5, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) announced today that representatives of the Company's wholly-owned subsidiary, Antigen Express, Inc., will be in attendance at the 2012 JPMorgan Healthcare Conference in San Francisco from January 8 through 13.
(Logo: http://photos.prne...
|
|
Generex Subsidiary Antigen Express Available for Partnering & Collaboration Meetings at the 2012 JPMorgan Healthcare Conference
Jan 4, 2012
|
12.1 KB |
| |
WORCESTER, Mass. and TORONTO, Jan. 4, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) announced today that representatives of the Company's wholly-owned subsidiary, Antigen Express, Inc., will be in attendance at the 2012 JPMorgan Healthcare Conference in San Francisco from January 8 through 13.
(Logo: http://photos.prnew...
|
|
Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
Jan 3, 2012
|
14.2 KB |
| |
WORCESTER, Mass. and TORONTO, Jan. 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37. Positive interim Phase 2b clinical data from the study in HER-2 expressing breast cancer subjects (presented last month at the 34th Annua...
|
|
Generex Announces Airing of Antigen Express Breast Cancer Vaccine Segment on Bloomberg Television
Dec 21, 2011
|
10.1 KB |
| |
WORCESTER, Mass. and TORONTO, Dec. 21, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that the previously announced Bloomberg Television segment on the Antigen Express breast cancer vaccine aired yesterday evening (December 20, 2011). The segment can be viewed on the Company's website at www.generex.com or ...
|
|
Generex Provides Update on Bloomberg TV Breast Cancer Vaccine Segment
Dec 20, 2011
|
9.5 KB |
| |
WORCESTER, Mass. and TORONTO, Dec. 20, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that the Bloomberg Television segment on the Antigen Express breast cancer vaccine did not air yesterday as originally scheduled (and announced in Bloomberg Television's December 16, 2011 promotional spot). The Company wil...
|
|
Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
Dec 19, 2011
|
12.6 KB |
| |
WORCESTER, Mass. and TORONTO, Dec. 19, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT.OB) today announced that Bloomberg Television is scheduled to air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. The segment is scheduled to air at 6 pm EST (3 pm ...
|
|
Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television
Dec 14, 2011
|
13.0 KB |
| |
WORCESTER, Mass. and TORONTO, Dec. 14, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that Bloomberg Television will air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc.
The story, expected to air December 19, 2011, will cov...
|
|
Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS
Dec 8, 2011
|
14.1 KB |
| |
WORCESTER, Mass. and TORONTO, Dec. 8, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that positive interim Phase 2 clinical data from its ongoing study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients were presented at the 34th Annual CTRC-AACR San An...
|
|
Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
Dec 7, 2011
|
49.2 KB |
| |
WORCESTER, Mass. and TORONTO, Dec. 7, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today that a group of physicians led by Professor Paolo Pozzilli at the University Campus Bio-Medico in Rome, Italy, will provide an update on results of using Generex Oral-lyn™ as it pertains to prediabetes ...
|
|
Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
Dec 1, 2011
|
11.9 KB |
| |
WORCESTER, Mass. and TORONTO, Dec. 1, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today provided an update on the status of the clinical and regulatory program for Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.
Work has been completed on reviewing, validating, re-ana...
|
|
Generex Subsidiary Antigen Express to Present AE37 Cancer Vaccine Phase 2 Clinical Data at 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
Nov 21, 2011
|
14.5 KB |
| |
WORCESTER, Mass. and TORONTO, Nov. 21, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) (www.generex.com) announced today that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will present new Phase 2 clinical data from its study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HE...
|
|
Generex Announces Investor Update Conference Call Planned for Late November
Oct 24, 2011
|
9.9 KB |
| |
WORCESTER, Mass. and TORONTO, Oct. 24, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) announced today that the Company is planning an investor update conference call for late November. The purpose of the call is to provide investors with an update on (i) the status of the Company's efforts in respect of the ...
|
|
Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
Oct 6, 2011
|
14.2 KB |
| |
WORCESTER, Mass. and TORONTO, Oct. 6, 2011 /PRNewswire/ -- Generex Biotechnology Corporation's (www.generex.com) (OTCBB: GNBT) wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com), today announced that the Company will be present at the Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, October 6,...
|
|
Antigen Express' AE37 Cancer Vaccine Featured in Scientific American
Sep 21, 2011
|
13.5 KB |
| |
WORCESTER, Mass. and TORONTO, Sept. 21, 2011 /PRNewswire/ -- Generex Biotechnology Corporation's (OTCBB: GNBT) (www.generex.com) wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), today announced that its lead drug candidate AE37, a novel HER-2/neu-targeted vaccine currently in Phase II development for the treatment of breast ...
|
|
Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
Sep 19, 2011
|
13.9 KB |
| |
WORCESTER, Mass. and TORONTO, Sept. 19, 2011 /PRNewswire/ -- Generex Biotechnology Corporation's (OTCBB: GNBT) (www.generex.com) wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), today announced that AE37, a novel HER-2/neu-targeted vaccine for the treatment of breast, prostate, and other cancers, is reviewed in the September...
|
|
Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
Sep 16, 2011
|
12.4 KB |
| |
WORCESTER, Mass. and TORONTO, Sept. 16, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today that Dr. Nicola Napolii, from University Campus Bio-Medico in Rome, Italy, made a podium presentation of the clinical data on Generex Oral-lyn™ buccal insulin spray on September 14, 2011 at the Europea...
|
|
Generex Provides Update on Spinout of Antigen Express
Sep 15, 2011
|
12.2 KB |
| |
WORCESTER, Mass. and TORONTO, Sept. 15, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today provided an update on the status of the previously announced spinout of its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).
The Company is in the midst of a detailed and comprehensive revie...
|
|
Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
Sep 7, 2011
|
10.1 KB |
| |
WORCESTER, Mass. and TORONTO, Sept. 7, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today that Mark Fletcher, the Company's President & Chief Executive Officer, and Dr. Eric von Hofe, President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com) will make a Gen...
|
|
Generex Augments Cash Position With Sales of Non-Essential Assets
Sep 6, 2011
|
9.4 KB |
| |
WORCESTER, Mass. and TORONTO, Sept. 6, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today that, as part of the Company's reorganization plan and following a comprehensive internal review of Company operations and a concomitant needs assessment, the Company has completed the sales of two non-essent...
|
|
Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program
Aug 18, 2011
|
12.4 KB |
| |
WORCESTER, Mass. and TORONTO, Aug. 18, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) announced today that the Company's wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com) presented an update of the ongoing Phase 2 trial with an off-the-shelf immunotherapeutic cancer vaccine, AE37, in pati...
|
|
Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
Aug 4, 2011
|
14.8 KB |
| |
SUNNYVALE, Calif. and TORONTO, Aug. 4, 2011 /PRNewswire/ -- Amarantus BioSciences (OTCBB: AMBS), a biotechnology company developing a first-in-class anti-apoptosis therapeutic protein known as MANF, and Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com), a biotechnology company developing a buccal insulin spray technology known as Ge...
|
|
Generex Provides Corporate Update
Aug 2, 2011
|
18.8 KB |
| |
WORCESTER, Mass. and TORONTO, Aug. 2, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) is pleased to provide its shareholders with a corporate update of developments that have been achieved since the appointment of Mark Fletcher as President & Chief Executive Officer on September 29, 2010.
"Since my appointm...
|
|
Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Jul 11, 2011
|
13.7 KB |
| |
WORCESTER, Mass. and TORONTO, July 11, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today the publication of studies conducted at the Mayo Clinic using the Antigen Express proprietary Ii-Key technology. Antigen Express, Inc., the Company's wholly-owned subsidiary, has used this technology platfor...
|
|
Generex Announces $2.575 Million Capital Investment
Jul 11, 2011
|
13.6 KB |
| |
WORCESTER, Mass., July 11, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (the "Company") (www.generex.com) (OTCBB: GNBT) today announced that it entered into a securities purchase agreement with certain institutional investors on July 8, 2011. The investors have agreed to purchase at the initial closing an aggregate of 2,575 shares of the...
|
|
Generex Provides Preliminary Results of Generex Oral-lyn™ Clinical Trials in Patients with Type 1 Diabetes and Patients with Impaired Glucose Tolerance
Jul 8, 2011
|
15.1 KB |
| |
WORCESTER, Mass. and TORONTO, July 8, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTC Bulletin Board: GNBT) (www.generex.com) today announced preliminary clinical results of two major trials using the Generex Oral-lyn™ formulation that will be used for registration and marketing. Unlike prior reported results from studies using o...
|
|
Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
Jul 5, 2011
|
12.7 KB |
| |
WORCESTER, Mass. and TORONTO, July 5, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today announced that it has engaged Congressman Curt Weldon to assist in supporting the strategic development plan unveiled by the Company at a press conference in New York City on March 30, 2011.
(Logo: http://photos.prne...
|
|
Generex Provides Clarification of Facts
Jun 27, 2011
|
13.0 KB |
| |
WORCESTER, Mass. and TORONTO, June 27, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today provided a clarification of facts arising out of a blog post on Friday, June 24, 2011. Following that blog post, the price of the Company's common stock fell more than 20% and more than 4 million shares were traded.
...
|
|
Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
Jun 16, 2011
|
13.9 KB |
| |
WORCESTER, Mass. and TORONTO, June 16, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today issued a synopsis of the update on the clinical and regulatory program for Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, provided at the annual meeting of the Company's stockholders h...
|
|
Generex Announces Appointment of CEO for Post-Spinout Antigen Express
Jun 15, 2011
|
11.5 KB |
| |
WORCESTER, Mass. and TORONTO, June 15, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today announced that Jos van der Woert has been appointed to act as Chief Executive Officer of its wholly-owned subsidiary, Antigen Express, Inc., following its spinout.
From 2003 to 2010, Mr. van der Woert was an executi...
|
|
Generex Announces Results of Annual Stockholders' Meeting
Jun 10, 2011
|
11.7 KB |
| |
WORCESTER, Mass. and TORONTO, June 10, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today announced the results of the Company's annual meeting of stockholders held on June 8, 2011.
(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)
At the annual meeting of stockholders, the following ...
|
|
Generex Biotechnology and Amarantus BioSciences Announce Oral-lyn-Focused Collaboration Program
Jun 8, 2011
|
15.8 KB |
| |
WORCESTER, MA and SUNNYVALE, CA -- (MARKET WIRE) -- 06/08/11 --
Generex Biotechnology (OTCBB: GNBT), a Massachusetts-based biotechnology company developing oral drug delivery technologies and Amarantus BioSciences, Inc. (OTCBB: AMBS), a California-based biotechnology company developing first-in-class proteins, today announced that the companie...
|
|
Generex Announces Mutual Decision Not to Proceed with Global Medical Direct Acquisition
Jun 6, 2011
|
11.7 KB |
| |
WORCESTER, Mass. and TORONTO, June 6, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today announced that the Company, together with Global Medical Direct, Inc. ("GMD") and its stockholders, have mutually decided not to proceed with the Company's previously announced acquisition of a 51% interest in GMD.
(...
|
|
Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
Jun 1, 2011
|
14.0 KB |
| |
WORCESTER, Mass. and TORONTO, June 1, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today announced that it intends to dividend a portion of the shares it receives upon completion of a definitive licensing agreement to license its RapidMist™ buccal drug delivery technologies to Amarantus BioSciences, I...
|
|
Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
May 31, 2011
|
14.3 KB |
| |
WORCESTER, Mass. and TORONTO, May 31, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today announced that it has entered into a binding letter agreement to license its RapidMist™ buccal drug delivery technologies to Amarantus BioSciences, Inc. (www.amarantus.com), a California-based biotechnology compan...
|
|
Generex Biotechnology Corporation CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
May 9, 2011
|
11.9 KB |
| |
NEW YORK, May 9, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC:GNBT) announced that their May 5th RetailInvestorConferences.com presentation is available for on-demand viewing.
LINK: www.retailinvestorconferences.com>Click the red "register/ watch event now" button.
Generex'spresentation will be available 24/7 ...
|
|
Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
May 3, 2011
|
12.2 KB |
| |
WORCESTER, Mass. and TORONTO, May 3, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced publication of results of studies applicable to the early diagnosis, and possibly treatment of, Type 1 diabetes. The study, entitled: "Recognition of Ii-Key/MHC Class II Epitope Hybrids Derived from Proinsulin...
|
|
|
